FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Market Closed - Börse Stuttgart 12:53:28 25/05/2024 am IST | ||
| 10.72 EUR | +10.74% |
|
| Current month | +10.86% | ||
| 1 month | +10.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 10.72 | +10.74% |
| 23/24/23 | 9.68 | -1.22% |
| 22/24/22 | 9.8 | +2.08% |
| 21/24/21 | 9.6 | -5.88% |
| 20/24/20 | 10.2 | +0.29% |
Delayed Quote Börse Stuttgart
Last update May 25, 2024 at 12:53 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1VGP |
| ISIN | DE000MG1VGP6 |
| Date issued | 08/04/2024 |
| Strike | 904.5 kr |
| Maturity | Unlimited |
| Parity | 3.98 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.05 € |
|---|---|
| Lowest since issue | 8.59 € |
| Spread | 0.18 € |
| Spread % | 1.65% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
586.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+33.94%
- Stock Market
- Certificates
- Certificat
